CU23691B7 - Derivados de pirazol fusionado y métodos de tratamiento de los desórdenes relacionados con el metabolismo - Google Patents
Derivados de pirazol fusionado y métodos de tratamiento de los desórdenes relacionados con el metabolismoInfo
- Publication number
- CU23691B7 CU23691B7 CU20070144A CU20070144A CU23691B7 CU 23691 B7 CU23691 B7 CU 23691B7 CU 20070144 A CU20070144 A CU 20070144A CU 20070144 A CU20070144 A CU 20070144A CU 23691 B7 CU23691 B7 CU 23691B7
- Authority
- CU
- Cuba
- Prior art keywords
- inhibitors
- compounds
- present
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Abstract
La presente invención se refiere a ciertos derivados de pirazol fusionado de fórmula (Ia), y a sus sales farmacéuticamente aceptables, que exhiben propiedades farmacológicas útiles, por ejemplo, como agonistas para el receptor RUP25. Por otra parte la presente invención proporciona composiciones farmacéuticas que contienen los compuestos de la invención, y métodos que usan los compuestos y composiciones de la invención en el tratamiento de desórdenes metabólico-relacionados, incluyendo dislipidemia, aterosclerosis, enfermedad coronaria, resistencia a la insulina, diabetes tipo 2, Síndrome-X y sus similares. Además, la presente invención también proporciona el uso de los compuestos de la invención en combinación con otros agentes activos tales como aquellos pertenecientes a la clase de los inhibidores alfa-glucosidasa, inhibidores de la aldosasa reductasa, biguanidas, inhibidores de la HMG-CoA reductasa, inhibidores de la síntesis de escualeno, fibratos, potenciadores del catabolismo LDL, inhibidores de la enzima convertidora de angiotensina (ACE), potenciadores de la secreción de insulina, antagonistas del receptor DP, y sus similares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63866804P | 2004-12-23 | 2004-12-23 | |
US67652105P | 2005-04-29 | 2005-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20070144A7 CU20070144A7 (es) | 2010-01-22 |
CU23691B7 true CU23691B7 (es) | 2011-09-21 |
Family
ID=36593187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20070144A CU23691B7 (es) | 2004-12-23 | 2007-06-20 | Derivados de pirazol fusionado y métodos de tratamiento de los desórdenes relacionados con el metabolismo |
Country Status (24)
Country | Link |
---|---|
US (3) | US7241792B2 (es) |
EP (1) | EP1831178A2 (es) |
JP (1) | JP2008525476A (es) |
KR (1) | KR20070088808A (es) |
CN (2) | CN102321024A (es) |
AR (1) | AR055015A1 (es) |
AU (1) | AU2005319121A1 (es) |
BR (1) | BRPI0519262A2 (es) |
CA (1) | CA2589648A1 (es) |
CU (1) | CU23691B7 (es) |
EA (1) | EA013184B1 (es) |
GE (1) | GEP20105126B (es) |
GT (1) | GT200500379A (es) |
HN (1) | HN2005036256A (es) |
IL (1) | IL183654A0 (es) |
MA (1) | MA29148B1 (es) |
NI (1) | NI200700161A (es) |
NO (1) | NO20073766L (es) |
NZ (1) | NZ555721A (es) |
PA (1) | PA8658301A1 (es) |
PE (1) | PE20060949A1 (es) |
TN (1) | TNSN07236A1 (es) |
TW (1) | TW200635904A (es) |
WO (1) | WO2006069242A2 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
ES2331521T3 (es) | 2003-11-21 | 2010-01-07 | Arena Pharmaceuticals, Inc. | Derivados de acido 4-oxo-4,5-dihidro-furan-2-carboxilico y procedimientos de tratamiento de trastornos metabolicos relacionados del mismo. |
PE20060949A1 (es) * | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
CA2611552A1 (en) | 2005-06-28 | 2007-01-04 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
EP2470552B1 (en) | 2009-08-26 | 2013-11-13 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
NZ598288A (en) * | 2009-08-28 | 2014-02-28 | Arena Pharm Inc | Cannabinoid receptor modulators |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
EP3385252B8 (en) * | 2011-02-25 | 2022-10-26 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
WO2012116278A1 (en) * | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
BR112013021549B1 (pt) | 2011-02-25 | 2022-01-11 | Arena Pharmaceuticals, Inc | Processos para preparação de forma cristalina anidra, para preparação de composição farmacêutica e para preparação de forma de dosagem, forma cristalina não solvatada anidra, composição farmacêutica, forma de dosagem, uso da referida forma cristalina e solvato |
WO2012116277A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP2015522080A (ja) | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3105336A (en) * | 1961-05-16 | 1963-10-01 | Package Machinery Co | Converting wrapping machines to wrap different size articles |
US4613610A (en) * | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
US5134155A (en) * | 1991-08-08 | 1992-07-28 | Ortho Pharmaceutical Corporation | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors |
WO2000007996A2 (en) * | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
BR0109050A (pt) | 2000-03-09 | 2004-04-27 | Ono Pharmaceutical Co | Derivados de indol, processo para prepapação e uso dos mesmos |
US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
JP4279561B2 (ja) | 2001-05-23 | 2009-06-17 | メルク フロスト カナダ リミテツド | プロスタグランジンD2受容体拮抗薬としてのジヒドロピロロ[1,2−a]インドールおよびテトラヒドロピリド[1,2−a]−インドール誘導体 |
EP1292602B1 (en) | 2001-06-27 | 2004-04-07 | RS Tech Corp. | New chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst |
JPWO2003022814A1 (ja) | 2001-09-07 | 2004-12-24 | 小野薬品工業株式会社 | インドール誘導体化合物 |
DE10148617A1 (de) * | 2001-09-25 | 2003-04-24 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
ES2365985T3 (es) | 2002-03-19 | 2011-10-14 | Ono Pharmaceutical Co., Ltd. | Compuestos de ácido carboxílico y fármacos que contienen los compuestos como ingrediente activo. |
AU2003282679A1 (en) | 2002-10-04 | 2004-05-04 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
CA2501134A1 (en) * | 2002-10-10 | 2004-04-22 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
WO2005011677A1 (en) * | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
GB0319126D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
GB0319124D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
KR101100601B1 (ko) | 2004-02-14 | 2011-12-29 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
PE20060949A1 (es) * | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
-
2005
- 2005-12-15 PE PE2005001472A patent/PE20060949A1/es not_active Application Discontinuation
- 2005-12-20 GT GT200500379A patent/GT200500379A/es unknown
- 2005-12-21 AR ARP050105438A patent/AR055015A1/es not_active Application Discontinuation
- 2005-12-21 HN HN2005036256A patent/HN2005036256A/es unknown
- 2005-12-21 TW TW094145549A patent/TW200635904A/zh unknown
- 2005-12-22 US US11/315,753 patent/US7241792B2/en active Active
- 2005-12-22 EA EA200701361A patent/EA013184B1/ru not_active IP Right Cessation
- 2005-12-22 CN CN2011102214069A patent/CN102321024A/zh active Pending
- 2005-12-22 CA CA002589648A patent/CA2589648A1/en not_active Abandoned
- 2005-12-22 GE GEAP200510188A patent/GEP20105126B/en unknown
- 2005-12-22 KR KR1020077016787A patent/KR20070088808A/ko not_active Application Discontinuation
- 2005-12-22 WO PCT/US2005/046599 patent/WO2006069242A2/en active Application Filing
- 2005-12-22 CN CN2011102214054A patent/CN102311378A/zh active Pending
- 2005-12-22 BR BRPI0519262-5A patent/BRPI0519262A2/pt not_active IP Right Cessation
- 2005-12-22 NZ NZ555721A patent/NZ555721A/en not_active IP Right Cessation
- 2005-12-22 EP EP05857182A patent/EP1831178A2/en not_active Withdrawn
- 2005-12-22 AU AU2005319121A patent/AU2005319121A1/en not_active Abandoned
- 2005-12-22 JP JP2007548472A patent/JP2008525476A/ja not_active Withdrawn
- 2005-12-23 PA PA20058658301A patent/PA8658301A1/es unknown
-
2006
- 2006-11-17 US US11/601,184 patent/US7612106B2/en not_active Expired - Fee Related
-
2007
- 2007-06-04 IL IL183654A patent/IL183654A0/en unknown
- 2007-06-20 TN TNP2007000236A patent/TNSN07236A1/fr unknown
- 2007-06-20 CU CU20070144A patent/CU23691B7/es not_active IP Right Cessation
- 2007-06-21 NI NI200700161A patent/NI200700161A/es unknown
- 2007-07-12 MA MA30071A patent/MA29148B1/fr unknown
- 2007-07-19 NO NO20073766A patent/NO20073766L/no not_active Application Discontinuation
-
2009
- 2009-04-30 US US12/433,704 patent/US20090258892A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GEP20105126B (en) | 2010-12-10 |
NZ555721A (en) | 2011-02-25 |
IL183654A0 (en) | 2007-09-20 |
GT200500379A (es) | 2006-10-25 |
TNSN07236A1 (en) | 2008-11-21 |
NO20073766L (no) | 2007-09-21 |
EA200701361A1 (ru) | 2007-12-28 |
WO2006069242A3 (en) | 2006-08-31 |
WO2006069242A2 (en) | 2006-06-29 |
BRPI0519262A2 (pt) | 2009-01-06 |
NI200700161A (es) | 2008-04-21 |
EP1831178A2 (en) | 2007-09-12 |
KR20070088808A (ko) | 2007-08-29 |
JP2008525476A (ja) | 2008-07-17 |
MA29148B1 (fr) | 2008-01-02 |
CU20070144A7 (es) | 2010-01-22 |
US20090258892A1 (en) | 2009-10-15 |
AU2005319121A1 (en) | 2006-06-29 |
US7241792B2 (en) | 2007-07-10 |
CA2589648A1 (en) | 2006-06-29 |
AR055015A1 (es) | 2007-08-01 |
HN2005036256A (es) | 2010-02-08 |
US20060205955A1 (en) | 2006-09-14 |
EA013184B1 (ru) | 2010-02-26 |
US20070073062A1 (en) | 2007-03-29 |
PA8658301A1 (es) | 2006-10-13 |
US7612106B2 (en) | 2009-11-03 |
PE20060949A1 (es) | 2006-10-11 |
TW200635904A (en) | 2006-10-16 |
CN102321024A (zh) | 2012-01-18 |
CN102311378A (zh) | 2012-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU23691B7 (es) | Derivados de pirazol fusionado y métodos de tratamiento de los desórdenes relacionados con el metabolismo | |
ECSP066529A (es) | Derivados de tetrazol y métodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
ATE459619T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
TW200635897A (en) | Piperidine derivatives and their use as anti-inflammatory agents | |
ECSP045519A (es) | Nuevos derivados de quinuclidina-amida | |
MX2008002062A (es) | Uso de derivados de tienopiridona como activadores de ampk y composiciones farmaceuticas que los contienen. | |
EA201071094A1 (ru) | Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
DE602005019043D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
EA200870448A1 (ru) | Тризамещенные 1,2,4-триазолы | |
CL2008002051A1 (es) | Compuestos derivados de isoxazol-4-metoxi, triazol-4-metoxi o pirazol-4-metoxi, con actividad agonista del receptor x de farnesoide (fxr); composicion farmaceutica que los contiene; y el uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento de dislipidemia y enfermedades relacionadas. | |
CL2012000708A1 (es) | Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. | |
CL2008002863A1 (es) | Compuestos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano sustituidos; el procedimiento de preparacion de los compuestos; su composicion farmaceutica; y uso en el tratamiento de la diabetes y enfermedades mediadas por glucocorticoides. | |
ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
ECSP088971A (es) | Ligandos 101 de los receptores nicotínicos de acetilcolina | |
UY28974A1 (es) | Derivados heterocíclicos de piperidina, composiciones que los contienen y procedimiento de preparación | |
RS54293B1 (en) | PHARMACEUTICAL COMBINATION | |
WO2005051937A8 (en) | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof | |
CR9178A (es) | Derivados de pirazol fusionado y metodos de tratamiento de los desordenes relacionados con el metabolismo | |
DOP2005000270A (es) | Derivados funsionados de pirazol y metodos de tratamiento de trastornos metabolicos co estos. | |
AR068342A1 (es) | Derivados heterociclios de sulfonamidas antagonistas del receptor b1 de bradiquinina | |
TH97655B (th) | สารประกอบไดแอลคิลฟีนิลที่มีฤทธิ์ (สูตร)2 อะดรีเนอร์จิครีเซพเตอร์อะโกนิสต์ และมัสคารินิครีเซพเตอร์แอนตาโกนิสต์ | |
AR060660A1 (es) | Derivado de 4-amino-2,6-dimetilfenol, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y usos en estados febriles o asociados al dolor. | |
AR095957A2 (es) | Un compuesto derivado de piperidinilo, composición farmaceutica que lo comprende y sus usos para la preparación de un medicamento | |
TH152421A (th) | เฮเทอโรไซคลิกซัลโฟนามีด การใช้และองค์ประกอบทางเภสัชกรรมของสารนั้น |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent | ||
FD | Lapse (for not paying fees) |